Autopsy report · NCT01643252

Safety and Efficacy Study for Corneal Collagen Cross-Linking in Eyes With Corneal Ectasia After Refractive Surgery

“This study was withdrawn for business reasons.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

Glaukos Corporation

Sponsor type

Industry

Conditions

Corneal Ectasia

Interventions

riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system; placebo: 0.0% riboflavin ophthalmic solution with the KXL system

Participants

0

Trials that died the same way

• Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEK162 in Noonan Syndrome Hypertrophic Cardiomyopathy
  “Study was withdrawn due to scientific and business considerations.” (92% match in meaning)
• Maxi-Analgesic Osteoarthritis (OA) Study
  “The study was withdrawn for administrative reason” (87% match in meaning)
• NRX-1074 in Early Course Schizophrenia
  “The study was withdrawn by the sponsor.” (86% match in meaning)
• Characteristic Analysis and Surgical Exploration for Acetabular Roof Fractures: Multicenter Retrospective Cohort Study
  “Due to limited funding, the study is now being withdrawn.” (85% match in meaning)
• A Study of the Safety and Efficacy of Pancreatic Endocrine Cell Clusters Implanted Into the Omentum of Type 1 Diabetes Patients With Severe Hypoglycemia
  “Study is being withdrawn for business reasons” (85% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.